Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine

Infection and Immunity

Volumn 70, Issue 4, 2002, Pages 1965-1970

  Cohen, Mitchell B ^a   Giannella, Ralph A ^a   Bean, Judy ^a   Taylor, David N ^a   Parker, Susan ^a   Hoeper, Amy ^a   Wowk, Stephen ^a   Hawkins, Jennifer ^a   Kochi, Sims K ^a   Schiff, Gilbert ^a   Killeen, Kevin P ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; CHOLERA VACCINE; LIVE VACCINE; PERU 15; PERU 15 VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; ARTICLE; BACTERIAL VIRULENCE; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DNA MODIFICATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; FECES COMPOSITION; GENE DELETION; GENETIC RECOMBINATION; GENETIC STABILITY; GENETIC STRAIN; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIBRIO CHOLERAE;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHOLERA VACCINES; DOUBLE-BLIND METHOD; HUMANS; VACCINATION; VACCINES, ATTENUATED;

EID: 0036128729     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.4.1965-1970.2002     Document Type: Article

References (17)

1. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique
2. Cholera outbreak among Rwandan refugees - Democratic Republic of Congo, April 1997
3. ABO blood groups and cholera: New observations on specificity of risk and modification of vaccine efficacy
4. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae
5. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance
6. Vaccines for preventing cholera
7. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1
8. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: Application in serodiagnosis and seroepidemiology
9. Duration of serum antitoxin response following Vibrio cholerae infection in North Americans: Relevance for seroepidemiology
10. Selective vs. non-selective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: Recommendations for clinical laboratories
11. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area
12. Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers
13. Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers
14. Validation of a volunteer model of cholera with frozen bacteria as the challenge
15. Cholera
16. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination
17. Development of a live, oral, attenuated vaccine against El Tor cholera